Anticancer research
-
Anticancer research · Jun 2013
Multicenter StudyPhase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chemotherapy plus trastuzumab is the standard first-line treatment for Human Epidermal Receptor 2-positive (HER2-positive) metastatic breast cancer. The aim of this international phase II trial was to determine the efficacy and safety profile of an oral chemotherapy doublet, oral vinorelbine plus capecitabine, and trastuzumab in this setting. ⋯ The triple combination of oral vinorelbine, capecitabine and trastuzumab is highly active in terms of response rate, progression-free survival and overall survival, with a manageable toxicity profile.
-
Anticancer research · Jun 2013
ReviewIs there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Studies carried out through the past two decades have evidenced that addition of bevacizumab to chemotherapy improves the efficacy both in first-line and second-line treatment in patients with metastatic colorectal cancer. Benefit of adding bevacizumab to second-line regimen after failing a bevacizumab-containing regimen, or aflibercept plus FOLFIRI) (irinotecan, 5-FU and leucovorin) after failing first-line oxaliplatin regimen with or without bevacizumab or regorafenib as a salvage therapy, do indicate the addiction to anti-vascular endothelial growth factor (VEGF) agents in these patients. This concept also lends some support from the NSABP C-08 adjuvant trial of colon cancer which showed very substantial improvement in time-to-recurrence for the one year of bevacizumab administration, but this benefit was quickly lost once the drug was stopped. The author reviews the data on anti-VEGF therapy in metastatic colorectal cancer.
-
Anticancer research · Jun 2013
Assessment of planning target volume margin for a small number of vertebral metastatic lesions using image-guided intensity-modulated radiation therapy by helical tomotherapy.
To evaluate an appropriate planning target volume (PTV) margin in for one to three vertebral metastases using megavolt computed tomography (MVCT) images during the course of image-guided and stereotactic intensity-modulated radiotherapy (IGRT-IMRT) by use of helical tomotherapy. ⋯ The PTV margin in hypofractionated IGRT-IMRT, using helical tomotherapy for a few vertebral metastases, was 2 mm or less and our tentative PTV margin of 5 mm was sufficient and reducible.
-
Anticancer research · May 2013
The implementation of minimally-invasive esophagectomy does not impact short-term outcome in a high-volume center.
Esophagectomy represents the gold standard in the treatment of resectable esophageal cancer. Despite significant improvements in perioperative care, postoperative morbidity and mortality rates remain high. Minimally-invasive surgical techniques introduced to the surgical treatment of esophageal malignancies have been shown to successfully diminish surgical trauma and postoperative morbidity. ⋯ The implementation of minimally-invasive esophagectomy is feasible, safe and has the potential to reduce perioperative morbidity without compromising oncological outcome.
-
Anticancer research · Apr 2013
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed. One approach for reducing toxicity is to use lower doses of sorafenib in combination with other complementary mechanisms. Celecoxib, a cyclooxygenase-2 inhibitor, has been shown to inhibit HCC, and we hypothesized that low-dose sorafenib co-administered with celecoxib could act synergistically in the inhibition of HCC. In this study, the effect of sorafenib was tested in combination with celecoxib on the growth of human HCC cells in vitro. ⋯ This study shows that celecoxib synergistically potentiates the sorafenib-mediated antitumor effect. This finding establishes the foundation for clinical trials evaluating the efficacy of co-administration of soerafenib and celecoxib as a treatment for HCC.